Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.

International journal of molecular sciences·2025
Same author

MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.

Frontiers in immunology·2025
Same author

The CD74 inhibitor DRhQ improves short-term memory and mitochondrial function in 5xFAD mouse model of Aβ accumulation.

Metabolic brain disease·2025
Same author

CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells.

PLoS biology·2024
Same author

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy.

Cancers·2024
Same author

MIF contribution to progressive brain diseases.

Journal of neuroinflammation·2024

Related Experiment Video

Updated: Jul 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Arthur A Vandenbark1, Rivka Abulafia-Lapid

  • 1Neuroimmunology Research, Veterans Affairs Medical Center, Department of Neurology, Oregon Health & Science University, Portland, Oregon 97207, USA. vandenba@ohsu.edu

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|July 10, 2008
PubMed
Summary

T-cell vaccination (TCV) offers a novel approach for multiple sclerosis (MS) by using modified T cells to regulate the immune response. This safe treatment shows potential for reducing MS relapses and improving patient stability.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Area of Science:

  • Immunology
  • Neurology
  • Vaccinology

Background:

  • Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation targeting myelin.
  • Current treatments for MS aim to manage symptoms and reduce disease activity.
  • T-cell vaccination (TCV) presents a unique immunomodulatory strategy for autoimmune conditions.

Purpose of the Study:

  • To evaluate the safety and efficacy of T-cell vaccination (TCV) in patients with multiple sclerosis (MS).
  • To investigate the potential of TCV to induce immune tolerance against myelin-reactive T cells.

Main Methods:

  • TCV involves administering irradiated, autologous myelin-reactive T cells to MS patients.
  • These attenuated T cells are designed to induce a regulatory immune response against pathogenic T cells.
  • Longitudinal studies monitor patient outcomes, including relapse rates and clinical status.

Main Results:

  • TCV has demonstrated a consistent safety profile in pilot trials.
  • A majority of treated MS patients experienced reduced relapse rates and clinical improvement, at least temporarily.
  • The findings support the role of inflammatory myelin-reactive T cells in MS pathogenesis.

Conclusions:

  • TCV is a safe and promising therapeutic strategy for multiple sclerosis (MS).
  • The approach warrants further investigation in larger clinical trials to confirm its long-term benefits.
  • TCV highlights the potential of targeted immune regulation in treating autoimmune neurological disorders.